DCIS (ductal carcinoma in situ) does not reliably go away on its own. While researchers have observed partial regression in some cases, where the body’s immune system attacks portions of the abnormal cells, studies show this process does not lead to complete disappearance of the disease. In untreated cases, an estimated 25 to 60% of DCIS progresses to invasive breast cancer over 9 to 24 years of follow-up.
That said, there’s growing recognition that not every case of DCIS needs aggressive treatment right away. The question isn’t really whether DCIS vanishes on its own, but whether some cases are so slow-growing that monitoring them closely is a reasonable alternative to immediate surgery.
What Partial Regression Actually Means
The body does mount an immune response against DCIS in some cases. A study published in the American Journal of Clinical Pathology found that signs of regression in high-grade DCIS are actually frequent, with immune cells infiltrating and partially destroying clusters of abnormal cells. This sounds encouraging, but the researchers reached a clear conclusion: the regression is only partial and does not lead to complete tumor elimination.
In fact, these regression changes tended to show up alongside more aggressive tumor characteristics, not less aggressive ones. The immune response appeared strongest against hormone receptor-negative DCIS, a subtype that generally carries higher risk. So while your immune system does recognize DCIS as abnormal, it can’t finish the job. Counting on spontaneous disappearance would be a gamble without scientific support.
The Risk of Doing Nothing
The 25 to 60% progression rate for untreated DCIS comes from studies tracking patients over one to two decades. That’s a wide range, and it reflects real differences between individual cases. Some DCIS is low-grade and slow-moving. Other cases are high-grade with features that look much closer to invasive cancer from the start.
The problem is that no one can predict with certainty which category a given case falls into. High-grade DCIS, which involves more abnormal-looking cells dividing more rapidly, carries a higher likelihood of becoming invasive. Low-grade DCIS progresses more slowly and less often, but “less often” is not “never.” This uncertainty is exactly why the standard approach has been to treat most DCIS with surgery, sometimes followed by radiation.
Why Some DCIS May Be Overtreated
The rise of routine mammography screening has dramatically increased the number of DCIS diagnoses. Before widespread screening, DCIS was relatively uncommon. Now it accounts for roughly 20 to 25% of all breast cancer diagnoses. Some of these cases would never have caused symptoms or threatened a woman’s life, a concept called overdiagnosis.
Researchers estimate that about 9% of screen-detected DCIS cases in U.S. women represent overdiagnosis, meaning the woman would have died of something else before the DCIS ever became a problem. This rate varies dramatically by age. For women screened at age 40, the overdiagnosis rate for DCIS is negligible (around 0.15%). By age 80, it climbs to roughly 30%, because competing health risks make it increasingly unlikely the DCIS would ever matter clinically.
This doesn’t mean the DCIS disappeared. It means the woman’s remaining lifespan was shorter than the time the DCIS would have needed to progress. For an older woman with other health conditions, treating a slow-growing DCIS with surgery and radiation may cause more harm than the disease itself ever would.
Active Monitoring as an Alternative
Three major clinical trials are currently investigating whether carefully selected DCIS patients can safely skip surgery in favor of close monitoring. The COMET trial (U.S.), LORD trial (Europe), and LORIS trial (U.K.) all enroll women with low-risk DCIS and track them with regular imaging instead of immediate surgical treatment.
Not everyone qualifies. When researchers applied the eligibility criteria from these trials to a group of 1,223 DCIS patients, only about one in five met the requirements. The biggest disqualifiers were high-grade DCIS and a visible mass on imaging. Among those who did qualify, roughly 7 to 8% were found to have invasive cancer when they eventually had tissue removed, suggesting their initial biopsy had missed a more serious component.
The monitoring protocol typically involves a diagnostic mammogram every six months, with detailed magnification views, plus an annual visit with a surgeon. Some patients opt for additional breast MRI based on personal preference, but mammography is the backbone of surveillance. The trials use specific triggers for recommending biopsy or surgery, such as calcifications growing by 5 mm (in COMET) or a 30% increase in size (in LORIS).
Genomic Testing and Treatment Decisions
A genomic test can help estimate recurrence risk for DCIS after breast-conserving surgery. The test analyzes a sample of the tumor tissue and produces a score that reflects how likely the DCIS is to come back. In a prospective study of 120 patients, about 48% received a low score, 25% an intermediate score, and 27% a high score.
For women with intermediate or high scores, the test agreed with radiation oncologists’ recommendations to proceed with radiation in nearly 97% of cases. More interestingly, it identified a small subgroup of patients with high or intermediate scores who had very small volumes of DCIS (under 10 mm) and could potentially skip radiation. This kind of precision matters because radiation after surgery reduces recurrence risk but also carries side effects, and some women may not need it.
What This Means Practically
If you’ve been diagnosed with DCIS and are wondering whether you can simply wait and see if it resolves, the honest answer is that complete spontaneous disappearance has not been documented. The biology doesn’t support a “wait and hope” approach. But that’s different from saying every DCIS diagnosis requires the same level of treatment.
For low-grade DCIS without a mass on imaging, active monitoring with frequent mammograms is being studied as a legitimate alternative to surgery. For higher-grade or larger DCIS, treatment remains the standard. Genomic testing can further refine the picture by identifying which patients benefit from radiation after surgery and which may safely skip it. The trend in DCIS management is toward more personalized decisions rather than one-size-fits-all treatment, but “personalized” still means close medical involvement, not walking away from a diagnosis.